Cancer poses a severe threat to human life and health. In recent years, immunotherapy has been widely used in cancer treatment. However, easy recurrence, drug resistance, and side effects have become urgent issues to be solved. Nano-drug delivery systems loaded with anti-tumor drugs have many advantages, including powerful targeting, high safety, and low side effects. Based on this, applying nano-drug delivery systems in immunotherapy is a research hotspot. This paper reviews the application status and research progress of nano-drug delivery systems in tumor immunotherapy. The history and types of nanocarriers and the current status of bispecific nanobodies and nucleic acid drugs are presented.

Ze Fang. Research on Nano-drug Delivery System in Tumor Immunotherapy. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 2: 23-31. https://doi.org/10.25236/IJFM.2024.060204.

[1] Tran Tuan Hiep, Nguyen Anh Ngoc, Kim Jong Oh, et al. Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers[J]. Artificial Cells, Nanomedicine, and Biotechnology, 2016, 44(8): 1979-1987.

[2] N. Jyotsana, A. Sharma, A. Chaturvedi, et al. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo[J]. 2019, 98: 1905-1918.        

[3] Jayesh A. Kulkarni, Maria M. Darjuan, A. Sharma, et al. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA [J]. ACS Nano, 2018, 12: 4787-4795.

[4] L.E. Swart, C.A. Koekman, C.W. Seinen, et al. A robust post-insertion method for the preparation of targeted siRNA LNPs [J]. International Journal of Pharmaceutics, 2022, 620: 121741.

[5] Williams C K. Synthesis of functionalized biodegradable polyesters [J]. Chem Soc Rev, 2007, 36(10): 1573-1580.

[6] Jain R K, Stylianopoulos T. Delivering nanomedicine to solid tumors [J]. Nat Rev Clin Oncol, 2010, 7(11): 653-664.

[7] Kai Chen, Shuangsi Liao, Shiwei Guo, et al. Multistimuli-responsive PEGylated polymeric bioconjugate-based nano-aggregate for cancer therapy [J]. Chemical Engineering Journal, 2020, 391: 123543.

[8] Zhang L, Liu Z, Kong C, et al. Improving drug delivery of micellar paclitaxel against non-small cell lung cancer by coloading itraconazole as a micelle stabilizer and a tumor vascular manipulator [J]. Small, 2018, 14(51). 

[9] Hossein Danafar, Amir Hossein Taromchi, Akram Rakhshbahar, et al. Co-delivery of methotrexate and curcumin with mPEG-PCL polymeric nanoparticles and evaluation of toxicity effect on MCF7 breast cancer cell line [J]. Inorganic Chemistry Communications, 2022, 142: 109715.

[10] Fang Luo. The prepartion and Application of nanoemulsion drug Delivery Vehicles [D]. Chang sha: Central South University, 2013.

[11] Zhang P, Wang J, Huang H, et al. Unexpected High Photothemal Conversion Efficiency of Gold Nanospheres upon Grafting with Two-Photon Luminescent Ruthenium(Ⅱ) Complexes: A Way towards Cancer Therapy[J]. Biomaterials, 2015, 63: 102-114.

[12] Stoddart, Liu Z, Lei J, et al. Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Cesoporous SilicaNanoparticles [J]. Chem. Soc, 2013, 135(31): 11603-11613.

[13] M.P. Zaborowski, L. Balaj, X.O. Breakefield, et al. Extracellular vesicles: Composition, biological relevance, and methods of study[J]. Bioscience, 2015, 65(8): 783-797.

[14] Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of Exosome Composition[J]. Cell, 2019, 177(2): 428-445.

[15] Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: A Web-Based Compendium of Exosomal Cargo [J]. J Mol Biol, 2016, 428(4): 688-692.

[16] Harmati M, Bukva M, Böröczky T, et al. The role of the metabolite cargo of extracellular vesicles in tumor progression [J]. Cancer Metastasis Rev, 2021, 40(4): 1203-1221.

[17] Bischoff JP, Schμlz A, Morrison H. The role of exosomes in inter-cellular and inter-organ communication of the peripheral nervous system[J]. FEBS Lett, 2022, 596(5): 655-664.

[18] Yujie Liang, Li Duan, Jianping Lu1, et al. Engineering exosomes for targeted drug delivery[J]. Theranostics, 2021, 11(7): 3183-3195.

[19] Siqing Zhu, Huiying Huang, Dong Liu, et al. Augmented cellular uptake and homologous targeting of exosome-based drug loaded IOL for posterior capsular opacification prevention and biosafety improvement [J]. Bioactive Materials, 2022, 15: 469-481.

[20] Tanziela Tanziela, Sana Shaikh, Fawad ur Rehman, et al. Cancer-exocytosed exosomes loaded with bio-assembled AgNCs as smart drug carriers for targeted chemotherapy[J]. Chemical Engineering Journal, 2022, 440: 135980.

[21] Guorong Zhang, Qin Wang, Wanyin Tao, et al. Glucosylated nanoparticles for the oral delivery of antibiotics to the proximal small intestine protect mice from gut dysbiosis [J]. Nature, 2022, 14. 

[22] S. Chowdhury, S. Castro, C. Coker, et al. T. DaninoProgrammable bacteria induce durable tumor regression and systemic antitumor immunity[J]. Nat. Med, 2019, 25: 1057-1063.

[23] C.R. Gurbatri, I. Lia, R. Vincent, et al. T. DaninoEngineered probiotics for local tumor delivery of checkpoint blockade nanobodies[J]. Sci. Transl. Med, 2020, 12.

[24] J.H. Zheng, V.H. Nguyen, S.N. Jiang, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin[J]. Sci. Transl. Med, 2017, 9.

[25] W. Huang, S. Wang, Y. Yao, et al. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection[J]. Sci. Rep, 2016, 6: 37242.

[26] Q. Liu, J. Yi, K. Liang, et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge[J]. Sci. Rep, 2016, 6: 34776.

[27] Nikkhoi S K, Rahbarizadeh F, Ranjbar S, et al. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting[J]. Molecular Immunology, 2018, 96: 98-109.

[28] Li Y M, Zhou C H, Li J, et al. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells[J]. PLoS One, 2018, 13(1): e0190124.

[29] Munter S, Ingels J, Goetgeluk G, et al. Nanobody based dual specific CARs[J]. International Journal of Molecular Sciences, 2018, 19(2): 403.

[30] Pan H T, Liu J Y, Deng W T, et al. Site-specific PEGylation of an anti-CEA/CD3 bispecificantibody improves its antitumor efficacy[J]. International Journal of Nanomedicine, 2018, 13: 3189-3201.

[31] Zhao Y N, Li Y M, Wu X Q, et al. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies[J]. Cancer Biology & Therapy, 2020, 21(1): 72-80.

[32] Pedersen D V, Rsner T, Hansen A G, et al. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement[J]. Molecular Immunology, 2020, 124: 200-210.

[33] Li H J, Zhao L, Wen B Y. Humanized bispecific nano antibody targeting EGFR (epidermal growth factor receptor) dimer interface: Chinese, 2020.

[34] Linlin Ma, Junwei Gai, Peng Qiao, et al. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade [J]. Biochemical and Biophysical Research Communications, 2020, 531(2): 144-151.

[35] Ma Jiabing, Zhao Wenxu, Xu Yanmin, et al. Bispecific antibody targeting CD96 and PD1[J]. Immunological Journal, 2022, 38(3): 269-276.

[36] Zhang F. Structural mechanisms of PD-L1 and CTLA-4 antibodies mediated tumor immunotherapy [D]. Shanghai: Shanghai Jiaotong University, 2018.

[37] Biologics W, Co S, Biologics W, et al. New programmed death 1 binding molecule comprising at least one immunoglobulin single variable domain: China, 2017.

[38] Wan Y K, Zhu M, Gai J W, et al. Anti-PD-L1/4-1BB bispecific antibody and use: Chinese, 2019.

[39] Tilman Schlothauer, Sylvia Herter, Christian Klein, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions[J]. Protein Engineering, Design & Selection, 2016, 29: 457-466.   

[40] Ma LL, Zhu M, Gai JW, et al. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential[J]. Journal of Nanobiotechnology, 2020, 18(1): 1-12.

[41] Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial[J]. Clinical Oncology, 2016, 39(18): 1959-1970.

[42] Li HJ, Zhao L, Wen BY. Humanized bispecific nano antibody targeting EGFR (epidermal growth factor receptor) dimer interface: Chinese, 2020.

[43] Pedersen DV, R sner T, Hansen AG, et al. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement[J]. Molecular Immunology, 2020, 124: 200-210.

[44] Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma[J]. Regular Article, 2018, 7: 1410-1415.

[45] Marina Bacac, Djamila Ouaret, Steffi Lehmann, et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors[J]. Clin Cancer Res, 2016, 22: 3286-3297.